ZYME - Zymeworks Inc. Common Stock logo

Zymeworks Inc. Common Stock

ZYME

Zymeworks Inc. develops biotherapeutics targeting cancer, inflammation, and autoimmune diseases using platforms like Azymetric and Drug Conjugate. Key products include bispecific antibodies for HER2-expressing tumors and antibody-drug conjugates for various cancers.

โš•๏ธ Healthcare NASDAQ Listed 2017 $ USD
$1,000 invested 5 years ago โ†’$1,237today

Score Overview

1 Year
Score
Net Growth-84.88%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-64.96%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score4.6
Net Growth29.20%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth39.16%
Rev Trend60%
Revenue Consistencyโ€”
All Time
Score
Net Growth-12x
Net Trend22%
Net Income Consistency
Rev Growth-28.27%
Rev Trend56%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Zymeworks Inc. Common Stock has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. ZYME does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-22
$ 28.44โ€”
1 Year2025-10-22
$ 17.6760.95%
5 Years2021-10-22
$ 23.0023.65%
All Time2017-04-28
$ 13.00118.77%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 37M-$ 149M$ 270.69B
2025$ 105M-$ 81M$ 228M
2024$ 76M-$ 122M$ 225M
2023$ 76M-$ 118M$ 374M
2022$ 412M$ 124M$ 492M
2021$ 26M-$ 211M$ 252M
2020$ 38M-$ 180M$ 426M
2019$ 29M-$ 145M$ 298M
2018$ 53M-$ 36M$ 200M
IPO2017$ 51M-$ 10M$ 87M
ZYME - Zymeworks Inc. Common Stock logo

Zymeworks Inc. Common Stock fundamental performance

Between 2020 and 2025, revenue grew from $ 38M to $ 105M and net income went from -$ 180M to -$ 81M. Revenue increased in 3 of those 5 years; net income in 2.

Across Zymeworks Inc. Common Stock's full reported history, from 2017 to 2025, revenue grew from $ 51M to $ 105M and net income went from -$ 10M to -$ 81M. Revenue increased in 56% of the years measured; net income in 22%.

Zymeworks Inc. Common Stock currently holds a 5-year HDB Score of 4.6 out of 10. How the HDB Score is calculated.

Membership

Explore ZYME with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,119 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies